Compare Carvana Co (CVNA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Incyte Corporation — how do they compare? Carvana Co trades at $63.8 (market cap $69.55B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Carvana Co is far larger — about 3× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Incyte Corporation for 33 Days on average.
| CVNA | INCY | |
|---|---|---|
Market Cap | $69.55B | $22.85B |
Volume | 7,671,750 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $129.93 |
52-Week Low | $56.27 | $83.80 |
Typical Hold Time | 28 Days | 33 Days |
Enterprise Value | $72.04B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.73, up 1.55% today, showing strong fundamental momentum with revenue surging to $20.32B in 2025 and net income reaching $1.41B. The stock has consistently beaten earnings expectations in recent quarters, though technical indicators signal bearish pressure with key resistance at $64-65. Recent news highlights Carvana as the 'best story' in autos with September sales beating estimates by 40%.
Carvana presents a compelling growth story with expanding profitability and aggressive capacity expansion, though high debt levels and volatile technical signals warrant caution. Analyst consensus targets $84.07 (32% upside) with 46% buy ratings, but investors face execution risks from inventory constraints and competitive pressures in the used car market.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
